To review post-translational modifications (PTMs) in retinoblastoma, focusing on their mechanisms, immune interactions, and implications for therapy.
Approach:
Review of PTMs: The article synthesizes current knowledge on PTMs related to RB-centered signaling, chromatin regulation, metabolic adaptation, and therapeutic resistance in retinoblastoma.
Evidence Hierarchy: It discusses the need for rigorous validation of PTM-related findings from various models before clinical application.
Clinical Translation: The commentary emphasizes the importance of ocular safety and biomarker validation in the context of retinoblastoma treatment.
Key Findings:
PTMs are biologically relevant in retinoblastoma and should be prioritized for further investigation.
Evidence from non-retinal cancer models should be considered as generating hypotheses rather than validated findings.
Therapeutic strategies must consider ocular pharmacokinetics and safety due to the unique anatomical challenges in retinoblastoma.
Interpretation:
Limitations:
Heterogeneous evidence streams complicate the integration of PTM findings into a cohesive therapeutic narrative.
Current PTM-targeting therapies require thorough validation in retinoblastoma-specific contexts.
Conclusion:
Future research should focus on validating PTM interventions specific to retinoblastoma.
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
